




RealRate

PHARMACEUTICAL 2021

Aeglea BioTherapeutics Inc.
Rank 241 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 160% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is -190%, being 164% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	149,789
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,443
Liabilities, Non-Current	5,343
Other Assets	6,187
Other Compr. Net Income	-40
Other Expenses	0
Other Liabilities	0
Other Net Income	588
Property and Equipment	5,642
Research and Development	59,638
Revenues	0
Selling, General and Administrative Expense	21,843

Output Variable	Value in 1000 USD
Assets	161,618
Liabilities	21,786
Expenses	81,481
Stockholders Equity	139,832
Net Income	-80,893
Comprehensive Net Income	-80,913
Economic Capital Ratio	-190%